首页> 外文期刊>Clinical nephrology >Serial ferritin concentrations in hemodialysis patients receiving intravenous iron.
【24h】

Serial ferritin concentrations in hemodialysis patients receiving intravenous iron.

机译:接受静脉铁剂治疗的血液透析患者中​​铁蛋白的系列浓度。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Treatment of the anemia of chronic renal failure with intravenous iron and erythropoietin is highly effective, but frequently leads to ferritin levels which are much higher than those seen in the general population. High ferritin concentrations raise concern about the potential toxicity of increased body iron stores. PATIENTS AND METHODS: We retrospectively evaluated parameters of iron metabolism over a 4-year period among all our chronic hemodialysis patients who had been receiving intravenous iron and erythropoietin. Initially, patients received intermittent infusions of 300 mg intravenous iron x 3 doses for a low ferritin or low percent saturation of total iron binding capacity (TIBC), but this protocol was subsequently changed to weekly or biweekly infusions of 50-100 mg. RESULTS: We observed an improvement in average hemoglobin values, modest increases in serum iron and saturation of iron binding capacity, and a 125% increase in ferritin levels over 4 years. TIBC decreased. Overall, ferritin values increased 79 microg/l for each 1% increase in TIBC saturation. Ten patients with ferritin concentration greater than 1,000 pg/l received a three month course of vitamin C with no decline in the ferritin concentration. CONCLUSION: Current protocols for iron delivery may result in progressive increases in ferritin levels. Concern about the risks of iron overload should temper the quantity of iron used in dialysis programs.
机译:背景:静脉注射铁和促红细胞生成素治疗慢性肾功能衰竭贫血非常有效,但通常导致铁蛋白水平大大高于普通人群。高铁蛋白浓度引起人们对体内铁储备增加的潜在毒性的关注。患者和方法:我们回顾性评估了所有接受静脉注射铁和促红细胞生成素的慢性血液透析患者在4年内铁代谢的参数。最初,患者因铁蛋白水平低或总铁结合能力(TIBC)饱和度低而接受300 mg静脉内输注x 3剂量的间歇性输注,但此方案随后改为每周或每两周输注50-100 mg。结果:我们观察到平均血红蛋白值有所改善,血清铁适度增加,铁结合能力饱和,并且在4年中铁蛋白水平增加了125%。 TIBC下降。总体而言,每增加1%TIBC饱和度,铁蛋白值就会增加79微克/升。铁蛋白浓度大于1,000 pg / l的十名患者接受了三个月的维生素C疗程,而铁蛋白浓度没有下降。结论:目前的铁释放方案可能导致铁蛋白水平逐渐升高。对铁超载风险的担忧应降低透析程序中使用的铁量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号